MIAMI Opko Health has decided to terminate its phase 3 trial of bevasiranib for treating wet age-related macular degeneration, the company announced in a press release.
The decision to conclude the clinical program follows a review of preliminary trial data by the Independent Data Monitoring Committee, which found that although bevasiranib showed activity when used in conjunction with Lucentis (ranibizumab, Genentech),
the trial was unlikely to meet its primary endpoint, the release said.
"While we are clearly disappointed with the preliminary results of this fully enrolled study, the indications of activity are encouraging, and we look forward to fully analyzing the data in the coming weeks," Phillip Frost, MD, chairman and chief executive officer of Opko Health, said in the release. "We remain committed to the continued development of our siRNA portfolio targeting vascular endothelial growth factor, including our recently announced VEGFA165b sparing siRNA."
The study identified no systemic or ocular safety issues with bevasiranib.